UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 221

Sortiert nach

Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer

Journal for immunotherapy of cancer, 2022-08, Vol.10 (8), p.e004757

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial

ESMO open, 2023-06, Vol.8 (3), p.101576-101576, Article 101576

2023

Link zum Volltext

Verfügbarkeit prüfen

Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients

Clinical & translational oncology, 2020-08, Vol.22 (8), p.1390-1398

2020

Link zum Volltext

Verfügbarkeit prüfen

nab-paclitaxel + carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND.sqm study

Annals of oncology, 2018-10, Vol.29, p.viii749-viii750

2018

Link zum Volltext

Verfügbarkeit prüfen

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis

Cancer treatment and research communications, 2021, Vol.27, p.100378, Article 100378

2021

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

Annals of oncology, 2023-05, Vol.34 (5), p.468-476

2023

Link zum Volltext

Verfügbarkeit prüfen

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

Annals of oncology, 2019-02, Vol.30 (2), p.290-296

2019

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

Annals of oncology, 2018-10, Vol.29 (10), p.2076-2084

2018

Link zum Volltext

Verfügbarkeit prüfen

From N-of-one to series of exceptional responders: unlocking the mystery of outliers in oncology

ESMO open, 2023-10, Vol.8 (5), p.101833-101833, Article 101833

2023

Link zum Volltext

Verfügbarkeit prüfen

Analysis of expression of PTEN/PI3 K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)

Lung cancer (Amsterdam, Netherlands), 2016-06

2016

Link zum Volltext

Verfügbarkeit prüfen

Maintenance treatment with the TLR9 agonist lefitolimod in extensive-stage small-cell lung cancer (ES-SCLC): Final results from the randomized phase II IMPULSE study

Annals of oncology, 2018-10, Vol.29, p.viii599-viii599

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii748-viii748

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer

Annals of oncology, 2018-10, Vol.29, p.viii413-viii413

2018

Link zum Volltext

Verfügbarkeit prüfen

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results

ESMO open, 2023-08, Vol.8 (4), p.101580-101580, Article 101580

2023

Link zum Volltext

Verfügbarkeit prüfen

Carcinoma of unknown origin: Deep genomic profile helps to achieve an accurate diagnosis

Annals of oncology, 2018-10, Vol.29, p.viii659-viii659

2018

Link zum Volltext

Verfügbarkeit prüfen

Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)

Lung cancer (Amsterdam, Netherlands), 2016-06, Vol.96, p.1-6

2016

Link zum Volltext

Verfügbarkeit prüfen

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2019-12, Vol.20 (12), p.1655-1669

2019

Link zum Volltext

Verfügbarkeit prüfen

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

The Lancet (British edition), 2016-04, Vol.387 (10030), p.1837-1846

2016

Link zum Volltext

Verfügbarkeit prüfen

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

The New England journal of medicine, 2018-06, Vol.378 (24), p.2288-2301

2018

Link zum Volltext

Verfügbarkeit prüfen

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2017-08, Vol.377 (9), p.829-838

2017

Link zum Volltext

Verfügbarkeit prüfen

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

The New England journal of medicine, 2014-12, Vol.371 (23), p.2167-2177

2014

Link zum Volltext

Verfügbarkeit prüfen

PD-7 Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma (aHCC) and previously treated gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJ): Results of the COSMIC-021 study

Annals of oncology, 2022-06, Vol.33, p.S241

2022

Link zum Volltext

Verfügbarkeit prüfen

1659P The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials

Annals of oncology, 2023-10, Vol.34, p.S913-S914

2023

Link zum Volltext

Verfügbarkeit prüfen

1161P Therapeutic outcome of molecular profiling of melanoma patients resistant to standard treatment: Real-world data

Annals of oncology, 2023-10, Vol.34, p.S692-S692

2023

Link zum Volltext

Verfügbarkeit prüfen

1416P Recurrence of infusion-related reaction (IRRs) associated to avimantamab

Annals of oncology, 2023-10, Vol.34, p.S809-S809

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 221

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(217)
Mit Volltextzugriff
(215)

Publikationsform

Artikel
(219)
Berichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(51)
Life Sciences & Biomedicine
(49)
Oncology
(45)
Humans
(38)
Female
(24)
Male
(24)
Lung Neoplasms - Drug Therapy
(21)
Lung Neoplasms - Pathology
(21)
Middle Aged
(20)
Aged
(19)
Lung Cancer
(17)
Lung Neoplasms - Genetics
(17)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(16)
Mutation
(16)
Respiratory System
(14)
Adult
(13)
Aged, 80 And Over
(13)
Carcinoma, Non-Small-Cell Lung - Pathology
(13)
Immunotherapy
(13)
Chemotherapy
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer

Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial

Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients

nab-paclitaxel + carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND.sqm study

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

From N-of-one to series of exceptional responders: unlocking the mystery of outliers in oncology

Analysis of expression of PTEN/PI3 K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)

Maintenance treatment with the TLR9 agonist lefitolimod in extensive-stage small-cell lung cancer (ES-SCLC): Final results from the randomized phase II IMPULSE study

Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC)

Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results

Carcinoma of unknown origin: Deep genomic profile helps to achieve an accurate diagnosis

Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

PD-7 Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma (aHCC) and previously treated gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJ): Results of the COSMIC-021 study

1659P The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials

1161P Therapeutic outcome of molecular profiling of melanoma patients resistant to standard treatment: Real-world data

1416P Recurrence of infusion-related reaction (IRRs) associated to avimantamab

Suchergebnisse filtern